DNA damage response inhibitors: An avenue for TNBC treatment
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Cancer Research,Genetics,Oncology
Reference127 articles.
1. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies;Denkert;Lancet (London, England),2017
2. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies;Lehmann;J. Clin. Invest.,2011
3. DNA repair dysregulation from cancer driver to therapeutic target;Curtin;Nat. Rev. Cancer,2012
4. Chk1 as a new therapeutic target in triple-negative breast cancer;Albiges;Breast,2014
5. Comprehensive molecular portraits of human breast tumours;Network;Nature,2012
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Transcriptional regulation of DLGAP5 by AR suppresses p53 signaling and inhibits CD8+ T cell infiltration in triple-negative breast cancer;Translational Oncology;2024-11
2. Research trends on nanomaterials in triple negative breast cancer (TNBC): a bibliometric analysis from 2010 to 2024;Drug Delivery and Translational Research;2024-09-06
3. MANCR lncRNA Modulates Cell-Cycle Progression and Metastasis by Cis-Regulation of Nuclear Rho-GEF;Molecular and Cellular Biology;2024-08-12
4. Hypoxia‐Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment‐Resistant Cancer Cells;Advanced Science;2024-07-08
5. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer;Scientific Reports;2024-05-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3